<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Clinical Trials - Latest News and Updates on Clinical Trials</title>
	<atom:link href="https://www.worldpharmatoday.com/clinical-trails/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Wed, 23 Sep 2026 11:26:06 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>Clinical Trials - Latest News and Updates on Clinical Trials</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Roche Obesity Drug Enicepatide Delivers 15.5% Weight Loss and Blood Sugar Reduction in Mid-Stage Trial</title>
		<link>https://www.worldpharmatoday.com/news/roche-obesity-drug-enicepatide-delivers-15-5-weight-loss-and-blood-sugar-reduction-in-mid-stage-trial/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 23 Sep 2026 11:26:06 +0000</pubDate>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/roche-obesity-drug-enicepatide-delivers-15-5-weight-loss-and-blood-sugar-reduction-in-mid-stage-trial/</guid>

					<description><![CDATA[<p>Swiss pharmaceutical company Roche has announced that its experimental dual-acting obesity drug, enicepatide, helped overweight or obese patients living with type 2 diabetes achieve an average body weight reduction of 15.5% while also significantly lowering blood sugar levels in a mid-stage clinical trial. The results position Roche as a serious contender in the rapidly expanding [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/roche-obesity-drug-enicepatide-delivers-15-5-weight-loss-and-blood-sugar-reduction-in-mid-stage-trial/">Roche Obesity Drug Enicepatide Delivers 15.5% Weight Loss and Blood Sugar Reduction in Mid-Stage Trial</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Clinical Trial Packaging for Investigational Product Management</title>
		<link>https://www.worldpharmatoday.com/clinical-trails/clinical-trial-packaging-for-investigational-product-management/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 14 Sep 2026 07:11:30 +0000</pubDate>
				<category><![CDATA[Clinical Trials]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/clinical-trial-packaging-for-investigational-product-management/</guid>

					<description><![CDATA[<p>The management of investigational products in the pharmaceutical sector requires a high level of precision to ensure the integrity of clinical data and the safety of trial participants. This specialized packaging serves a critical role that goes far beyond the simple containment of medication. It is the primary interface between the clinical supply chain and [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/clinical-trails/clinical-trial-packaging-for-investigational-product-management/">Clinical Trial Packaging for Investigational Product Management</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Digital Supply Chain Platforms Improving Clinical Supply Visibility</title>
		<link>https://www.worldpharmatoday.com/clinical-trails/digital-supply-chain-platforms-improving-clinical-supply-visibility/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 05 Sep 2026 08:14:43 +0000</pubDate>
				<category><![CDATA[Clinical Trials]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/digital-supply-chain-platforms-improving-clinical-supply-visibility/</guid>

					<description><![CDATA[<p>The management of supplies for clinical trials has traditionally been one of the most complex and fragmented parts of the pharmaceutical product lifecycle. Unlike commercial distribution, which often follows predictable patterns, clinical logistics must handle small, patient-specific kits that move through a global network of depots and trial sites. Any disruption in this chain can [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/clinical-trails/digital-supply-chain-platforms-improving-clinical-supply-visibility/">Digital Supply Chain Platforms Improving Clinical Supply Visibility</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>AI-Driven Clinical Trials Are Closing the Speed Gap</title>
		<link>https://www.worldpharmatoday.com/clinical-trails/ai-driven-clinical-trials-are-closing-the-speed-gap/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 27 Jun 2026 07:49:01 +0000</pubDate>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Techno Trends]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/ai-driven-clinical-trials-are-closing-the-speed-gap/</guid>

					<description><![CDATA[<p>The pharmaceutical industry has long struggled with the bottleneck of clinical development. While the discovery of new drug candidates has accelerated through advanced computation and genomics, the process of testing these molecules in human subjects remains slow, expensive, and prone to failure. On average, it takes over a decade and billions of dollars to bring [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/clinical-trails/ai-driven-clinical-trials-are-closing-the-speed-gap/">AI-Driven Clinical Trials Are Closing the Speed Gap</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>US Clinical Trials Plan Aims to Restore Research Leadership</title>
		<link>https://www.worldpharmatoday.com/news/us-clinical-trials-plan-aims-to-restore-research-leadership/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 24 Jun 2026 13:15:03 +0000</pubDate>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/us-clinical-trials-plan-aims-to-restore-research-leadership/</guid>

					<description><![CDATA[<p>The US Department of Health and Human Services (HHS) has outlined a new strategy aimed at reinforcing the country’s position in pharmaceutical research as competition from China intensifies. Through an initiative called Operation Trailblazer, HHS plans to introduce measures designed to accelerate drug development, reduce delays in clinical studies, expand participation in research programmes, and [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/us-clinical-trials-plan-aims-to-restore-research-leadership/">US Clinical Trials Plan Aims to Restore Research Leadership</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Insilico Medicine Advances ISM8969 Into Phase 1 Trial as Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation</title>
		<link>https://www.worldpharmatoday.com/news/insilico-medicine-advances-ism8969-into-phase-1-trial-as-brain-penetrant-nlrp3-inhibitor-for-neuroinflammation/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 19 Jun 2026 07:39:02 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Techno Trends]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/insilico-medicine-advances-ism8969-into-phase-1-trial-as-brain-penetrant-nlrp3-inhibitor-for-neuroinflammation/</guid>

					<description><![CDATA[<p>Insilico Medicine has reached a significant clinical milestone with the completion of first-in-human dosing of ISM8969 in a Phase 1 study. Conducted in collaboration with Hygtia Therapeutics, the ISM8969 Phase 1 trial marks the transition of this oral, brain-penetrant NLRP3 inflammasome inhibitor from preclinical development into human evaluation. The compound is designed to address chronic [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/insilico-medicine-advances-ism8969-into-phase-1-trial-as-brain-penetrant-nlrp3-inhibitor-for-neuroinflammation/">Insilico Medicine Advances ISM8969 Into Phase 1 Trial as Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Boehringer&#8217;s Survodutide Cuts Visceral and Liver Fat While Preserving Lean Mass in Late-Stage Trial</title>
		<link>https://www.worldpharmatoday.com/news/boehringers-survodutide-cuts-visceral-and-liver-fat-while-preserving-lean-mass-in-late-stage-trial/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 09 Jun 2026 07:45:56 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/boehringers-survodutide-cuts-visceral-and-liver-fat-while-preserving-lean-mass-in-late-stage-trial/</guid>

					<description><![CDATA[<p>German pharmaceutical company Boehringer Ingelheim has reported that its experimental obesity drug, survodutide, significantly reduced visceral abdominal fat and liver fat while largely preserving lean body mass in a late-stage clinical study. The data strengthens the company&#8217;s argument that the drug offers meaningful health benefits beyond overall weight loss percentage a distinction that analysts have [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/boehringers-survodutide-cuts-visceral-and-liver-fat-while-preserving-lean-mass-in-late-stage-trial/">Boehringer’s Survodutide Cuts Visceral and Liver Fat While Preserving Lean Mass in Late-Stage Trial</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>MSD and Adcendo Initiate Phase Ib Collaboration for Solid Tumours</title>
		<link>https://www.worldpharmatoday.com/news/msd-and-adcendo-initiate-phase-ib-collaboration-for-solid-tumours/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 29 May 2026 13:23:20 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/msd-and-adcendo-initiate-phase-ib-collaboration-for-solid-tumours/</guid>

					<description><![CDATA[<p>MSD and Adcendo have established a collaboration and supply agreement to evaluate the combination of ADCE-T02 and pembrolizumab. The companies are preparing for a Phase Ib solid tumour clinical trial targeting patients with advanced solid tumours. Adcendo will act as the sponsor for the solid tumour clinical trial, with MSD providing pembrolizumab. ADCE-T02 is an [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/msd-and-adcendo-initiate-phase-ib-collaboration-for-solid-tumours/">MSD and Adcendo Initiate Phase Ib Collaboration for Solid Tumours</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Decentralized Clinical Trials Market Advances Worldwide</title>
		<link>https://www.worldpharmatoday.com/clinical-trails/decentralized-clinical-trials-market-advances-worldwide/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 20 May 2026 10:35:31 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Telehealth]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/decentralized-clinical-trials-market-advances-worldwide/</guid>

					<description><![CDATA[<p>The global Decentralized Clinical Trials Market is expected to grow from USD 9.74 billion in 2025 to USD 34.13 billion by 2035, registering a compound annual growth rate (CAGR) of 13.36% during the forecast period from 2026 to 2035. The market is expanding as pharmaceutical companies, biotechnology firms, contract research organizations, and healthcare technology providers [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/clinical-trails/decentralized-clinical-trials-market-advances-worldwide/">Decentralized Clinical Trials Market Advances Worldwide</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Algeria and Hungary Enhance Pharmaceutical Industry Collaboration via R&#038;D and Clinical Trials</title>
		<link>https://www.worldpharmatoday.com/news/algeria-and-hungary-enhance-pharmaceutical-industry-collaboration-via-rd-and-clinical-trials/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 19 May 2026 13:26:27 +0000</pubDate>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/algeria-and-hungary-enhance-pharmaceutical-industry-collaboration-via-rd-and-clinical-trials/</guid>

					<description><![CDATA[<p>In a strategic move to bolster the national pharmaceutical industry, the Algerian Minister of Pharmaceutical Industry, Mr. Wassim Kouidri, convened with the Ambassador of the Republic of Hungary, Mr. Gábor Levente Szarka, this Sunday in Algiers. The high-level discussions centered on intensifying bilateral cooperation between the two nations, with a specific focus on research and [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/algeria-and-hungary-enhance-pharmaceutical-industry-collaboration-via-rd-and-clinical-trials/">Algeria and Hungary Enhance Pharmaceutical Industry Collaboration via R&D and Clinical Trials</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
